TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q2 2025
Holdings as of Jun 30, 2025, filed Aug 14, 2025. Long positions only; changes compare share counts with Q1 2025.
- Positions
- 37
- 0 vs. Q1 2025
- Portfolio value
- $875.5M
- +$142.4M (+19.4%) vs. Q1 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CGONCG Oncology, Inc. | COM | 3,670,206 | $95.4M | 10.9% | 00.0% | Unchanged | History |
| TNGXTango Therapeutics, Inc. | COM | 10,736,000 | $55.0M | 6.3% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 6,964,375 | $50.0M | 5.7% | 00.0% | Unchanged | History |
| OCULOcular Therapeutix, Inc | COM | 5,319,148 | $49.4M | 5.6% | 00.0% | Unchanged | History |
| CDTXCidara Therapeutics, Inc. | COM NEW | 1,005,901 | $49.0M | 5.6% | 00.0% | Unchanged | History |
| ABVXAbivax S.A. | SPONSORED ADS | 6,056,596 | $46.3M | 5.3% | 00.0% | Unchanged | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 5,943,812 | $38.1M | 4.4% | 00.0% | Unchanged | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 2,890,816 | $38.0M | 4.3% | 00.0% | Unchanged | History |
| FULCFulcrum Therapeutics, Inc. | COM | 5,250,000 | $36.1M | 4.1% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 3,766,660 | $35.9M | 4.1% | +1,116,510+42.1% | Added | History |
| EYPTEyePoint, Inc. | COM NEW | 3,572,335 | $33.6M | 3.8% | 00.0% | Unchanged | History |
| UPBUpstream Bio, Inc. | COM | 2,801,763 | $30.8M | 3.5% | 00.0% | Unchanged | History |
| SVRASavara Inc | COM | 12,362,205 | $28.2M | 3.2% | 00.0% | Unchanged | History |
| DNTHDianthus Therapeutics, Inc. | COM | 1,501,624 | $28.0M | 3.2% | 00.0% | Unchanged | History |
| TYRATyra Biosciences, Inc. | COM | 2,898,103 | $27.7M | 3.2% | 00.0% | Unchanged | History |
| IRONDisc Medicine, Inc. | COM | 465,257 | $24.6M | 2.8% | 00.0% | Unchanged | History |
| TRMLTourmaline Bio, Inc. | COM | 1,477,593 | $23.6M | 2.7% | 00.0% | Unchanged | History |
| AGIOAgios Pharmaceuticals, Inc. | COM | 697,003 | $23.2M | 2.6% | +697,003 | New | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 1,063,000 | $22.0M | 2.5% | 00.0% | Unchanged | History |
| XNCRXencor Inc | COM | 2,452,138 | $19.3M | 2.2% | 00.0% | Unchanged | History |
| SLNSilence Therapeutics plc | ADS | 3,033,560 | $17.6M | 2.0% | 00.0% | Unchanged | History |
| SLNOSoleno Therapeutics Inc | COM | 186,250 | $15.6M | 1.8% | −88,750−32.3% | Reduced | History |
| ATXSAstria Therapeutics, Inc. | COM | 2,761,861 | $14.8M | 1.7% | 00.0% | Unchanged | History |
| RAPTRAPT Therapeutics, Inc. | COM NEW | 1,636,275 | $13.1M | 1.5% | +1,636,275 | New | History |
| THRDThird Harmonic Bio, Inc. | COM | 1,915,424 | $10.4M | 1.2% | −590,000−23.5% | Reduced | History |
| ELVNEnliven Therapeutics, Inc. | COM | 498,000 | $9.99M | 1.1% | +498,000 | New | History |
| MBXMBX Biosciences, Inc. | COM | 650,000 | $7.42M | 0.8% | 00.0% | Unchanged | History |
| NKTRNektar Therapeutics | COM NEW | 266,666 | $6.89M | 0.8% | 00.0% | UnchangedConverted for a 1-for-15 split | History |
| VTGNVistagen Therapeutics, Inc. | COM | 2,676,580 | $5.35M | 0.6% | 00.0% | Unchanged | History |
| KODKodiak Sciences Inc. | COM | 1,145,538 | $4.27M | 0.5% | 00.0% | Unchanged | History |
| KURAKura Oncology, Inc. | COM | 735,184 | $4.24M | 0.5% | −688,458−48.4% | Reduced | History |
| TRDAEntrada Therapeutics, Inc. | COM | 584,955 | $3.93M | 0.4% | 00.0% | Unchanged | History |
| ADVMAdverum Biotechnologies, Inc. | COM NEW | 1,796,482 | $3.86M | 0.4% | 00.0% | Unchanged | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 483,000 | $2.41M | 0.3% | 00.0% | Unchanged | History |
| VTYXVentyx Biosciences, Inc. | COM | 316,195 | $676.7K | 0.1% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM NEW | 64,023 | $639.6K | 0.1% | +64,023 | New | History |
| CABACabaletta Bio, Inc. | COM | 86,795 | $131.9K | <0.1% | 00.0% | Unchanged | History |
Sold out since Q1 2025 (4)
Positions held at the end of Q1 2025 that are gone from this filing.
| Security | Class | Shares in Q1 2025 | Value in Q1 2025 | % of portfolio in Q1 2025 | History |
|---|---|---|---|---|---|
| MLYSMineralys Therapeutics, Inc. | COM | 2,470,265 | $39.2M | 5.4% | History |
| RAPTRAPT Therapeutics, Inc. | COM | 13,090,200 | $16.0M | 2.2% | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 3,858,000 | $11.0M | 1.5% | History |
| JBIOJade Biosciences, Inc. | COM | 2,240,809 | $5.62M | 0.8% | History |